ProShares Ultra Nasdaq Biotechnology Rating $114.52 +0.26 (+0.23%) As of 03:58 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsSEC Filings ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BIB Aggregate RatingModerate Buy 2.69Holdings in BIB have an aggregate rating of Moderate Buy based on 402 analyst ratings issued in the past year covering 19 companies (31.2% of the portfolio).BIB Aggregate Price Target$113.99-0.08% DownsideHigh Prediction$113.99Average Prediction$113.99Low Prediction$113.99Holdings in BIB have an aggregate price target of $113.99 and a range of $113.99 to $113.99 covering 19 companies (31.2% of the portfolio).BIB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy11 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 19 BIB Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings4.39%VRTXVertex Pharmaceuticals$526.38+0.8%Moderate Buy$573.83 9.0%233.5736 of 5 stars4.27%AMGNAmgen$414.76+2.1%Hold$383.46 -7.5%303.4512 of 5 starsAnalyst ForecastAnalyst Revision4.08%GILDGilead Sciences$150.86+0.8%Moderate Buy$158.78 5.2%293.999 of 5 starsAnalyst Revision2.93%REGNRegeneron Pharmaceuticals$787.84-1.0%Moderate Buy$802.18 1.8%243.6577 of 5 stars2.08%MRNAModerna$198.89+2.1%Hold$76.72 -61.4%241.9755 of 5 starsTrending NewsAnalyst Forecast1.58%RVMDRevolution Medicines$205.26+2.7%Buy$230.15 12.1%233.106 of 5 starsAnalyst UpgradeInsider Trade1.21%ALNYAlnylam Pharmaceuticals$255.88+2.5%Moderate Buy$367.20 43.5%233.7931 of 5 stars1.17%BIIBBiogen$227.78+0.6%Moderate Buy$230.14 1.0%322.3977 of 5 stars1.14%ILMNIllumina$270.12-1.4%Hold$199.13 -26.3%182.1815 of 5 starsTrending News1.07%ROIVRoivant Sciences$35.79-0.9%Moderate Buy$45.64 27.5%133.0412 of 5 starsAnalyst Forecast1.02%INSMInsmed$118.10-2.8%Buy$201.87 70.9%253.6595 of 5 starsAnalyst Upgrade0.99%ARGXargenex$959.07-0.3%Moderate Buy$1,158.61 20.8%244.3652 of 5 stars0.95%RPRXRoyalty Pharma$58.25-0.1%Buy$61.29 5.2%84.1346 of 5 starsInsider Trade0.88%INCYIncyte$123.91-0.4%Moderate Buy$124.05 0.1%252.8317 of 5 starsAnalyst Forecast0.77%UTHRUnited Therapeutics$475.74+0.7%Moderate Buy$621.00 30.5%144.3992 of 5 starsTrending NewsAnalyst UpgradeInsider Trade0.76%GHGuardant Health$177.17+0.4%Moderate Buy$188.13 6.2%251.9573 of 5 stars0.70%VTRSViatris$17.85+2.5%Moderate Buy$19.50 9.2%92.9689 of 5 starsNews CoverageAnalyst Forecast0.61%MEDPMedpace$618.26-0.4%Hold$595.20 -3.7%122.42 of 5 starsInsider Trade0.59%ASNDAscendis Pharma A/S$225.78-2.1%Buy$310.75 37.6%214.8019 of 5 stars This page (NASDAQ:BIB) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIB Stock Alerts